Latest Breaking News On - Michael molyneaux - Page 8 : comparemela.com

Sirnaomics Doses First Patient in Phase 2 Study of STP705 for Keloid Scar Prevention

Sirnaomics Doses First Patient in Phase 2 Study of STP705 for Keloid Scar Prevention
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesMark corbaeStephanie carringtonMichael molyneauxPatrick luSirnaomics incChief medical officerChief executive officerOrphan drug designationGlobal visionPatient centeredMedical officerஒன்றுபட்டது மாநிலங்களில்மாற்றாந்தாய் கேரிங்டன்மைக்கேல் மோலிநிபேட்ரிக் லு

Sirnaomics Receives FDA Approval of IND for Phase 1 Clinical Trial of Systemic RNAi Therapeutic STP707 for Solid Tumor Treatment

Sirnaomics Receives FDA Approval of IND for Phase 1 Clinical Trial of Systemic RNAi Therapeutic STP707 for Solid Tumor Treatment
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesMark corbaeStephanie carringtonMichael molyneauxPatrick luPrnewswire sirnaomics incLysine coDrug administrationSirnaomics incDose escalation studyDose expansion studyAntitumor activityChief medical officerHistidine lysine co polymerGlobal visionPatient centered

Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma

Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma News provided by Share this article Share this article GAITHERSBURG, Md. and SUZHOU BIOBAY, China, June 16, 2021 /PRNewswire/ Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases, and other unmet clinical indications, today announced that the China National Medical Product Administration (NMPA) has accepted its Investigational New Drug (IND) application for the company s lead candidate, STP705, for the treatment of skin squamous cell carcinoma in situ (isSCC).

United statesMark corbaeStephanie carringtonMichael molyneauxPatrick luInternational agency for research on cancerA world health organizationDrug administrationChina national medical product administrationSirnaomics incInvestigational new drugChief medical officerCutaneous responseNon melanoma skin cancerWorld health organizationOrphan drug designation

Sirnaomics Initiates Phase 2b Study Using STP705 for Treatment of Squamous Cell Skin Cancer

Sirnaomics Initiates Phase 2b Study Using STP705 for Treatment of Squamous Cell Skin Cancer Company Expects to Report Initial Clinical Data in Second Half of 2021 News provided by Share this article Share this article GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 25, 2021 /PRNewswire/ Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced the initiation of the Phase 2b study of the company s lead drug candidate, STP705, for the treatment of squamous cell skin cancer. The randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of intralesional injection of STP705 in 100 adult patients with squamous cell carcinoma

United statesMark corbaeStephanie carringtonMichael molyneauxPatrick luInternational agency for research on cancerA world health organizationSirnaomics incChief medical officerNon melanoma skin cancerWorld health organizationOrphan drug designationGlobal visionPatient centeredMedical officerஒன்றுபட்டது மாநிலங்களில்

Sirnaomics Initiates Phase 2 Study Using STP705 for Keloid Scar Prevention

Sirnaomics Initiates Phase 2 Study Using STP705 for Keloid Scar Prevention Company Expects to Report Interim Clinical Data in the Second Half of 2021 News provided by Share this article Share this article GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 18, 2021 /PRNewswire/ Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced the initiation of a Phase 2 study of the company s lead drug candidate, STP705, for Keloid scar prevention. The Phase 2, multi-center, randomized, double-blind, multiple-arm, controlled study is designed to evaluate the safety and efficacy of various doses of STP705 in reducing post-keloidectomy keloid recurrence.

United statesMark corbaeStephanie carringtonMichael molyneauxPatrick luSiranomics incSirnaomics incChief medicalOrphan drug designationGlobal visionPatient centeredMedical officerஒன்றுபட்டது மாநிலங்களில்மாற்றாந்தாய் கேரிங்டன்மைக்கேல் மோலிநிபேட்ரிக் லு